The industry analysis specialist’s new report, “Atrial Fibrillation – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global atrial fibrillation therapeutics market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global atrial fibrillation market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides a valuable insight into the pipeline products within the global atrial fibrillation therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The scope of the report includes:
- Annualized global atrial fibrillation therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include Factor Xa Inhibitors, direct thrombin inhibitors,A1 adenosine receptor agonists, multiple and selective ion channel blockers and gap junction inhibitors.
- Analysis of the current and future market competition in the global atrial fibrillation therapeutics market. Key market players covered are Bayer Healthcare, Proctor and Gamble, Boehringer Ingelheim, Sanofi Aventis, Cardiome Pharma Corp and Astellas Pharma US and Xention Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with atrial fibrillation.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global atrial fibrillation therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments, and companies likely to impact the global atrial fibrillation therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- What’s the next big thing in the global atrial fibrillation market landscape? Identify, understand, and capitalize.
To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/
